Sativa Wellness - Launch of 8 more COVID Testing Facilities
RNS Number : 8091P
Sativa Wellness Group Inc.
22 February 2021
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION (INCLUDING THE UNITED STATES) WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.

Sativa Wellness Group Inc.
("Sativa" or "Sativa Wellness" the "Company" or the "Group")

22 February 2021

 

Launch of 8 more COVID Testing Facilities

 

Sativa Wellness Group is pleased to announce that our Bath and Bristol Goodbody clinics booked up to £27,000 a day in COVID testing revenues in December. Having proved the testing model in Bath and Bristol, we have rolled out a number of in-pharmacy clinics and today we open our tenth testing facility with a further twenty in-pharmacy clinics in process.

Current clinics are located in:

Bath
Bristol
Swindon
Exeter
London
Reading
Cardiff
Newport
Southampton
Cheltenham

The company is well placed to benefit from the expected easing of UK travel restrictions at the end of this lock down period.

Geremy Thomas, Executive Chairman, says: "The prospects for the company are very positive. Recent restructuring has improved our cash runway, ensuring our cash reserves remain robust.  New wellness revenue streams are set to increase substantially and existing CBD revenues are anticipated to rebound as the High Street recovers from the pandemic."   

The Directors of the Company accept responsibility for the contents of this announcement.

On behalf of the Board of Directors,

 

Geremy Thomas

Executive Chairman

Sativa Wellness Group Inc.

+44 (0) 20 7971 1255

enquiries@sativawellnessgroup.com

 www.sativawellnessgroup.com

Joseph Colliver

Chief Financial Officer

Sativa Wellness Group Inc.

+44 (0) 20 7971 1255

enquiries@sativawellnessgroup.com

 www.sativawellnessgroup.com

 

 

 

 

AQSE Growth Market Corporate Adviser

Peterhouse Capital Limited

Guy Miller/Allie Feuerlein

+ 44 (0) 20 7220 9795 

 

 

This information is provided by RNS, the news service of the . RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXBBGDDCSDDGBB ]]>